



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK Invited to Project Pitch Stage For GAPP Application

Vancouver, British Columbia – (February 21, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is proud to announce that it has been successful in the first round of Genome Canada’s Genomic Applications Partnership Program (GAPP) Expression Of Interest submission. BioMark has now been invited to proceed to the Project Pitch Stage that will include a review committee of independent experts.

President and CEO, Rashid Ahmed says, “BioMark is excited to pass through this round of the competition. The estimated project budget is estimated at over \$3 million. The funding will be focused on accelerating the commercialization of our metabolomics based diagnostics for lung cancer initially.” BioMark would like to take this opportunity to thank all the clinical, regulatory and technology advisors and partners for their support during the application process. Information regarding future successful development related to this program will be announced.

About Genome Canada GAPP

The Genomic Applications Partnership Program (GAPP) represents a key element in Genome Canada’s strategic plan towards funding downstream research and development (R&D) projects that are driven by challenges and opportunities facing users of genomics based technologies. For the purpose of this program, “Users” include the various stakeholders that have an interest in “pulling” technologies and other results of genomics research from academia to market and application, including industry, government, not-for-profits, and other organizations.

The GAPP aims to:

- Promote the application of genomics-derived solutions to address key sector challenges or opportunities facing Users – User “pull”;
- Promote commercialization of genomics technologies by enabling the transfer of genomics-derived solutions from Academia to Users as well as de-risking and incentivizing follow-on investment from public and private partners;
- Increase the socio-economic impact of genomics research by accelerating its translation to application or market; and,
- Create and foster a more productive interface between Academia and Users.

Key Parameters of the Program:

Total project size: \$300,000 to \$6 million. The structure of the funding plan is as follows: 1/3 investment from Genome Canada, 1/3 provided by the User partner (cash or in-kind) and 1/3 of other co-funding

Project term: 1-3 years. A shorter or longer term will be considered, but only if a strong rationale is provided.

- Project stage: small-scale proof-of-concept or pilot projects through to large-scale projects. Projects should not be in the discovery phase.

To be eligible for the GAPP, a project must:

- respond to the objectives of the GAPP
- represent an active partnership between Academic(s) and User(s)
- propose to develop, enhance or validate a genomics-derived solution (i.e., a product, tool or process whose origin is based in genomics or related disciplines such as bioinformatics, epigenomics, metabolomics, metagenomics, nutrigenomics, pharmacogenomics, proteomics and transcriptomics);
- address key challenges or opportunities defined by the User that require a partnership with Academia (i.e., User “pull”); and
- focus on downstream R&D activities.

Application Process

There is a three-stage gated application process for this program:

1. Expression of Interest (EOI)
2. Project Pitch
3. Supplementary Proposal

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com